
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeiGene's financial position is robust, closing 2024 with US$2.6 billion in cash, which provides a solid foundation for ongoing operations and potential expansions. The company experienced significant growth in its core drug, Brukinsa, achieving a 105% year-over-year increase in sales to US$2.6 billion, indicating strong market demand and momentum. Additionally, BeiGene's other product, Tevimbra, reported a 16% increase in sales, further demonstrating the company's competitive positioning in the oncology market and enhancing its future revenue projections.
Bears say
BeiGene is experiencing a concerning financial trajectory, as evidenced by a significant drop in cash flow from financing operations, which fell from US$188 million in the third quarter to US$75 million in the fourth quarter of 2024 due to increased receivables and inventory. The company recorded a net loss of US$645 million, although this represents a narrowing of 27% year-over-year. Projections indicate minimal revenue growth in mature markets for 2025, combined with downward revisions to sales estimates for key products, reflecting significant potential downside risks for the stock.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares